CA3033749A1 - Compositions and methods for detecting rare sequence variants - Google Patents
Compositions and methods for detecting rare sequence variants Download PDFInfo
- Publication number
- CA3033749A1 CA3033749A1 CA3033749A CA3033749A CA3033749A1 CA 3033749 A1 CA3033749 A1 CA 3033749A1 CA 3033749 A CA3033749 A CA 3033749A CA 3033749 A CA3033749 A CA 3033749A CA 3033749 A1 CA3033749 A1 CA 3033749A1
- Authority
- CA
- Canada
- Prior art keywords
- polynucleotides
- sequence
- polynucleotide
- sample
- sequencing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 335
- 239000000203 mixture Substances 0.000 title abstract description 19
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 911
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 911
- 239000002157 polynucleotide Substances 0.000 claims abstract description 911
- 238000012163 sequencing technique Methods 0.000 claims abstract description 298
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 82
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 74
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 74
- 230000003321 amplification Effects 0.000 claims description 255
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 255
- 125000003729 nucleotide group Chemical group 0.000 claims description 150
- 239000002773 nucleotide Substances 0.000 claims description 145
- 108020004414 DNA Proteins 0.000 claims description 139
- 238000006243 chemical reaction Methods 0.000 claims description 102
- 108091028732 Concatemer Proteins 0.000 claims description 93
- 102000003960 Ligases Human genes 0.000 claims description 71
- 108090000364 Ligases Proteins 0.000 claims description 71
- 230000000295 complement effect Effects 0.000 claims description 58
- 238000001514 detection method Methods 0.000 claims description 54
- 206010028980 Neoplasm Diseases 0.000 claims description 51
- 230000002068 genetic effect Effects 0.000 claims description 40
- 239000011541 reaction mixture Substances 0.000 claims description 39
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 30
- 238000005096 rolling process Methods 0.000 claims description 30
- 238000005304 joining Methods 0.000 claims description 29
- 238000004458 analytical method Methods 0.000 claims description 27
- 230000027455 binding Effects 0.000 claims description 26
- 230000001364 causal effect Effects 0.000 claims description 24
- 230000000593 degrading effect Effects 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 20
- 108091035707 Consensus sequence Proteins 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 238000010008 shearing Methods 0.000 claims description 17
- 108091092259 cell-free RNA Proteins 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 210000004881 tumor cell Anatomy 0.000 claims description 15
- 210000001124 body fluid Anatomy 0.000 claims description 14
- 238000006073 displacement reaction Methods 0.000 claims description 13
- 210000002700 urine Anatomy 0.000 claims description 13
- 238000004925 denaturation Methods 0.000 claims description 12
- 230000036425 denaturation Effects 0.000 claims description 12
- 239000012188 paraffin wax Substances 0.000 claims description 11
- 210000003296 saliva Anatomy 0.000 claims description 11
- 238000000527 sonication Methods 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 9
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 239000012569 microbial contaminant Substances 0.000 claims description 4
- 239000000523 sample Substances 0.000 description 203
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 183
- 208000035475 disorder Diseases 0.000 description 157
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 125
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 description 125
- 239000000047 product Substances 0.000 description 70
- 239000012634 fragment Substances 0.000 description 49
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 45
- 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 45
- 230000008569 process Effects 0.000 description 44
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 40
- 108091034117 Oligonucleotide Proteins 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 36
- 238000009396 hybridization Methods 0.000 description 33
- 208000005980 beta thalassemia Diseases 0.000 description 32
- 238000011282 treatment Methods 0.000 description 30
- 238000003752 polymerase chain reaction Methods 0.000 description 29
- 201000006288 alpha thalassemia Diseases 0.000 description 27
- 238000013467 fragmentation Methods 0.000 description 27
- 238000006062 fragmentation reaction Methods 0.000 description 27
- 201000010099 disease Diseases 0.000 description 26
- 238000012217 deletion Methods 0.000 description 25
- 230000037430 deletion Effects 0.000 description 25
- 238000004422 calculation algorithm Methods 0.000 description 24
- 108020004705 Codon Proteins 0.000 description 23
- 102000053602 DNA Human genes 0.000 description 23
- 230000000875 corresponding effect Effects 0.000 description 23
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 22
- 238000000605 extraction Methods 0.000 description 22
- 230000000670 limiting effect Effects 0.000 description 19
- 230000035772 mutation Effects 0.000 description 19
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 108091092878 Microsatellite Proteins 0.000 description 18
- 108020004682 Single-Stranded DNA Proteins 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 18
- 102000054765 polymorphisms of proteins Human genes 0.000 description 18
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 206010000021 21-hydroxylase deficiency Diseases 0.000 description 15
- 238000000137 annealing Methods 0.000 description 15
- 238000012545 processing Methods 0.000 description 15
- 238000002955 isolation Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 102000012410 DNA Ligases Human genes 0.000 description 12
- 108010061982 DNA Ligases Proteins 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 206010001689 alkaptonuria Diseases 0.000 description 12
- 238000013461 design Methods 0.000 description 12
- 102000054767 gene variant Human genes 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- -1 but not limited to Proteins 0.000 description 11
- 238000010348 incorporation Methods 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108091093088 Amplicon Proteins 0.000 description 10
- 102000036365 BRCA1 Human genes 0.000 description 10
- 108700020463 BRCA1 Proteins 0.000 description 10
- 101150072950 BRCA1 gene Proteins 0.000 description 10
- 108060002716 Exonuclease Proteins 0.000 description 10
- 102000035195 Peptidases Human genes 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 10
- 239000004365 Protease Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 102000013165 exonuclease Human genes 0.000 description 10
- 239000000178 monomer Substances 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 208000006992 Color Vision Defects Diseases 0.000 description 9
- 206010011777 Cystinosis Diseases 0.000 description 9
- 201000000761 achromatopsia Diseases 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 206010071434 biotinidase deficiency Diseases 0.000 description 9
- 210000000481 breast Anatomy 0.000 description 9
- 201000007254 color blindness Diseases 0.000 description 9
- 238000011109 contamination Methods 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 230000002611 ovarian Effects 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 102000052609 BRCA2 Human genes 0.000 description 8
- 108700020462 BRCA2 Proteins 0.000 description 8
- 101150008921 Brca2 gene Proteins 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 108020004418 ribosomal RNA Proteins 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 102100029140 Cyclic nucleotide-gated cation channel beta-3 Human genes 0.000 description 7
- 102100031089 Cystinosin Human genes 0.000 description 7
- 108010067770 Endopeptidase K Proteins 0.000 description 7
- 101000771083 Homo sapiens Cyclic nucleotide-gated cation channel beta-3 Proteins 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 7
- 238000010804 cDNA synthesis Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 208000008106 junctional epidermolysis bullosa Diseases 0.000 description 7
- 201000001334 junctional epidermolysis bullosa Herlitz type Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000005291 magnetic effect Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 108091070501 miRNA Proteins 0.000 description 7
- 239000002679 microRNA Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 235000019419 proteases Nutrition 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 6
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100034782 Homogentisate 1,2-dioxygenase Human genes 0.000 description 6
- 108020004566 Transfer RNA Proteins 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000003505 heat denaturation Methods 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 102100026044 Biotinidase Human genes 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108020005196 Mitochondrial DNA Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 201000007219 factor XI deficiency Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000037452 priming Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108700022487 rRNA Genes Proteins 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 4
- 208000009766 Blau syndrome Diseases 0.000 description 4
- 208000005692 Bloom Syndrome Diseases 0.000 description 4
- 102100035631 Bloom syndrome protein Human genes 0.000 description 4
- 208000022526 Canavan disease Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 206010011878 Deafness Diseases 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 208000022206 Hemoglobin C-beta-thalassemia syndrome Diseases 0.000 description 4
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 4
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 4
- 101000861263 Homo sapiens Steroid 21-hydroxylase Proteins 0.000 description 4
- 208000004891 Shellfish Poisoning Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 102100027545 Steroid 21-hydroxylase Human genes 0.000 description 4
- 208000002903 Thalassemia Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 4
- 235000011180 diphosphates Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000013412 genome amplification Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 231100000888 hearing loss Toxicity 0.000 description 4
- 230000010370 hearing loss Effects 0.000 description 4
- 208000016354 hearing loss disease Diseases 0.000 description 4
- 238000012165 high-throughput sequencing Methods 0.000 description 4
- 201000008980 hyperinsulinism Diseases 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000002753 trypsin inhibitor Substances 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 102100024645 ATP-binding cassette sub-family C member 8 Human genes 0.000 description 3
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 3
- 102100029470 Apolipoprotein E Human genes 0.000 description 3
- 241000203069 Archaea Species 0.000 description 3
- 206010068220 Aspartylglucosaminuria Diseases 0.000 description 3
- 102100036465 Autoimmune regulator Human genes 0.000 description 3
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000001730 Familial dysautonomia Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 101000760570 Homo sapiens ATP-binding cassette sub-family C member 8 Proteins 0.000 description 3
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 3
- 101000979046 Homo sapiens Lysosomal alpha-mannosidase Proteins 0.000 description 3
- 206010020608 Hypercoagulation Diseases 0.000 description 3
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 3
- 102100024629 Laminin subunit beta-3 Human genes 0.000 description 3
- 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 3
- 102100023231 Lysosomal alpha-mannosidase Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 101710086015 RNA ligase Proteins 0.000 description 3
- 201000001638 Riley-Day syndrome Diseases 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 3
- 201000008333 alpha-mannosidosis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000002680 canonical nucleotide group Chemical group 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 230000001973 epigenetic effect Effects 0.000 description 3
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 238000011901 isothermal amplification Methods 0.000 description 3
- 108010028309 kalinin Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 208000009928 nephrosis Diseases 0.000 description 3
- 231100001027 nephrosis Toxicity 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 102200011922 rs11466024 Human genes 0.000 description 3
- 102200132384 rs28940279 Human genes 0.000 description 3
- 102200132368 rs28940574 Human genes 0.000 description 3
- 102200009200 rs28940578 Human genes 0.000 description 3
- 102200009211 rs28940579 Human genes 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 201000005665 thrombophilia Diseases 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 2
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 2
- FWXNJWAXBVMBGL-UHFFFAOYSA-N 9-n,9-n,10-n,10-n-tetrakis(4-methylphenyl)anthracene-9,10-diamine Chemical compound C1=CC(C)=CC=C1N(C=1C2=CC=CC=C2C(N(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=C2C=CC=CC2=1)C1=CC=C(C)C=C1 FWXNJWAXBVMBGL-UHFFFAOYSA-N 0.000 description 2
- 101150037123 APOE gene Proteins 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 208000000363 Agenesis of Corpus Callosum Diseases 0.000 description 2
- 102100032948 Aspartoacylase Human genes 0.000 description 2
- 208000001827 Ataxia with vitamin E deficiency Diseases 0.000 description 2
- 102100021296 Bardet-Biedl syndrome 10 protein Human genes 0.000 description 2
- 102220582796 Biotinidase_A171T_mutation Human genes 0.000 description 2
- 102220582802 Biotinidase_D444H_mutation Human genes 0.000 description 2
- 101100179597 Caenorhabditis elegans ins-7 gene Proteins 0.000 description 2
- 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 description 2
- 208000004918 Cartilage-hair hypoplasia Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 206010008723 Chondrodystrophy Diseases 0.000 description 2
- 208000033810 Choroidal dystrophy Diseases 0.000 description 2
- 102100040996 Cochlin Human genes 0.000 description 2
- 208000008020 Cohen syndrome Diseases 0.000 description 2
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 2
- 108010060248 DNA Ligase ATP Proteins 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 102000018825 Fanconi Anemia Complementation Group C protein Human genes 0.000 description 2
- 201000004939 Fanconi anemia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000978730 Homo sapiens Nephrin Proteins 0.000 description 2
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 2
- 101001094831 Homo sapiens Phosphomannomutase 2 Proteins 0.000 description 2
- 101000662686 Homo sapiens Torsin-1A Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108091023242 Internal transcribed spacer Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- 102100023195 Nephrin Human genes 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102100035362 Phosphomannomutase 2 Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100039233 Pyrin Human genes 0.000 description 2
- 108010059278 Pyrin Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 2
- 101710179516 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 2
- 108091006633 SLC12A6 Proteins 0.000 description 2
- 102100034272 Sacsin Human genes 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 102100034245 Solute carrier family 12 member 6 Human genes 0.000 description 2
- 102220611126 Steroid 21-hydroxylase_M239K_mutation Human genes 0.000 description 2
- 102220611123 Steroid 21-hydroxylase_V237E_mutation Human genes 0.000 description 2
- 102220611084 Steroid 21-hydroxylase_V281L_mutation Human genes 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102100037454 Torsin-1A Human genes 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 2
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000008919 achondroplasia Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 102220389303 c.457_458insG Human genes 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 102000028861 calmodulin binding Human genes 0.000 description 2
- 108091000084 calmodulin binding Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000003571 choroideremia Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 208000030448 congenital disorder of glycosylation Ia Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007847 digital PCR Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 208000016570 early-onset generalized limb-onset dystonia Diseases 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 108010091897 factor V Leiden Proteins 0.000 description 2
- 244000078673 foodborn pathogen Species 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000007827 neuronopathy Effects 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 102200011971 rs104895085 Human genes 0.000 description 2
- 102200009196 rs104895094 Human genes 0.000 description 2
- 102200009215 rs104895097 Human genes 0.000 description 2
- 102200011921 rs11466023 Human genes 0.000 description 2
- 102220001118 rs180177327 Human genes 0.000 description 2
- 102200146742 rs2066844 Human genes 0.000 description 2
- 102200146596 rs2066845 Human genes 0.000 description 2
- 102200108731 rs28928906 Human genes 0.000 description 2
- 102200070479 rs28933693 Human genes 0.000 description 2
- 102200011981 rs28940580 Human genes 0.000 description 2
- 102200132016 rs34911792 Human genes 0.000 description 2
- 102200132012 rs36210737 Human genes 0.000 description 2
- 102200012155 rs3743930 Human genes 0.000 description 2
- 102220022565 rs386833672 Human genes 0.000 description 2
- 102220022567 rs386833676 Human genes 0.000 description 2
- 102220001006 rs386833969 Human genes 0.000 description 2
- 102220002036 rs397515360 Human genes 0.000 description 2
- 102200009213 rs61732874 Human genes 0.000 description 2
- 102200009203 rs61752717 Human genes 0.000 description 2
- 102220005204 rs63750783 Human genes 0.000 description 2
- 102220220688 rs746566500 Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000010865 sewage Substances 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000001847 surface plasmon resonance imaging Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108020004565 5.8S Ribosomal RNA Proteins 0.000 description 1
- 108020005075 5S Ribosomal RNA Proteins 0.000 description 1
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- 102100032123 AMP deaminase 1 Human genes 0.000 description 1
- 102000000872 ATM Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 208000033337 Alpha-sarcoglycan-related limb-girdle muscular dystrophy R3 Diseases 0.000 description 1
- 108010063905 Ampligase Proteins 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- 102100022794 Bestrophin-1 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100030686 Beta-sarcoglycan Human genes 0.000 description 1
- 208000034067 Beta-sarcoglycan-related limb-girdle muscular dystrophy R4 Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150029409 CFTR gene Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108700005857 Carnitine palmitoyl transferase 1A deficiency Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 206010007747 Cataract congenital Diseases 0.000 description 1
- 108020004998 Chloroplast DNA Proteins 0.000 description 1
- 102100029057 Coagulation factor XIII A chain Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000019057 Cytochrome P-450 CYP2C19 Human genes 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108020001738 DNA Glycosylase Proteins 0.000 description 1
- 102000008158 DNA Ligase ATP Human genes 0.000 description 1
- 102000028381 DNA glycosylase Human genes 0.000 description 1
- 102100029995 DNA ligase 1 Human genes 0.000 description 1
- 101710148291 DNA ligase 1 Proteins 0.000 description 1
- 102100033195 DNA ligase 4 Human genes 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 102000004099 Deoxyribonuclease (Pyrimidine Dimer) Human genes 0.000 description 1
- 108010082610 Deoxyribonuclease (Pyrimidine Dimer) Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 206010066054 Dysmorphism Diseases 0.000 description 1
- 102100039246 Elongator complex protein 1 Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 101900063352 Escherichia coli DNA ligase Proteins 0.000 description 1
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 201000007371 Factor XIII Deficiency Diseases 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 1
- 101000703495 Homo sapiens Beta-sarcoglycan Proteins 0.000 description 1
- 101000813117 Homo sapiens Elongator complex protein 1 Proteins 0.000 description 1
- 101000725943 Homo sapiens RNA polymerase II subunit A C-terminal domain phosphatase Proteins 0.000 description 1
- 101000641122 Homo sapiens Sacsin Proteins 0.000 description 1
- 101000690425 Homo sapiens Type-1 angiotensin II receptor Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108700036248 MT-RNR1 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000194105 Paenibacillus polymyxa Species 0.000 description 1
- 241001523956 Parengyodontium album Species 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000370518 Phytophthora ramorum Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 102100027669 RNA polymerase II subunit A C-terminal domain phosphatase Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 101100385043 Sus scrofa CYP21 gene Proteins 0.000 description 1
- 108091012456 T4 RNA ligase 1 Proteins 0.000 description 1
- 101000803944 Thermus filiformis DNA ligase Proteins 0.000 description 1
- 101000803951 Thermus scotoductus DNA ligase Proteins 0.000 description 1
- 101000803959 Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8) DNA ligase Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102100026803 Type-1 angiotensin II receptor Human genes 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 201000003554 argininosuccinic aciduria Diseases 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000009561 autosomal recessive limb-girdle muscular dystrophy type 2D Diseases 0.000 description 1
- 201000009553 autosomal recessive limb-girdle muscular dystrophy type 2E Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 102220383392 c.1024G>A Human genes 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 108091092240 circulating cell-free DNA Proteins 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 239000003653 coastal water Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000030483 congenital disorder of glycosylation Ib Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 244000000037 crop pathogen Species 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 239000003239 environmental mutagen Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000021393 food security Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 101150055609 fusA gene Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 101150013736 gyrB gene Proteins 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229940115931 listeria monocytogenes Drugs 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 235000019689 luncheon sausage Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 208000011130 pituitary stalk interruption syndrome Diseases 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 208000022563 qualitative or quantitative defects of alpha-sarcoglycan Diseases 0.000 description 1
- 208000022561 qualitative or quantitative defects of beta-sarcoglycan Diseases 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 101150090202 rpoB gene Proteins 0.000 description 1
- 102200012160 rs104895079 Human genes 0.000 description 1
- 102200011914 rs104895081 Human genes 0.000 description 1
- 102200011945 rs104895083 Human genes 0.000 description 1
- 102200146728 rs104895460 Human genes 0.000 description 1
- 102200146888 rs104895461 Human genes 0.000 description 1
- 102200146887 rs104895462 Human genes 0.000 description 1
- 102200146910 rs104895477 Human genes 0.000 description 1
- 102220159921 rs1057515669 Human genes 0.000 description 1
- 102220005333 rs111033603 Human genes 0.000 description 1
- 102200015489 rs113624356 Human genes 0.000 description 1
- 102200026972 rs113994206 Human genes 0.000 description 1
- 102200027330 rs113994208 Human genes 0.000 description 1
- 102200021797 rs120074170 Human genes 0.000 description 1
- 102200021816 rs120074173 Human genes 0.000 description 1
- 102200022183 rs120074174 Human genes 0.000 description 1
- 102220001485 rs121908035 Human genes 0.000 description 1
- 102200128615 rs121908750 Human genes 0.000 description 1
- 102200128186 rs121908752 Human genes 0.000 description 1
- 102200128167 rs121908753 Human genes 0.000 description 1
- 102200128232 rs121908758 Human genes 0.000 description 1
- 102200128270 rs121908759 Human genes 0.000 description 1
- 102200128201 rs121909011 Human genes 0.000 description 1
- 102200062447 rs121909239 Human genes 0.000 description 1
- 102200049506 rs121964904 Human genes 0.000 description 1
- 102200092097 rs12713559 Human genes 0.000 description 1
- 102200111022 rs1303 Human genes 0.000 description 1
- 102200147805 rs137852672 Human genes 0.000 description 1
- 102220002617 rs137853042 Human genes 0.000 description 1
- 102220277100 rs1553412518 Human genes 0.000 description 1
- 102220285047 rs1555575370 Human genes 0.000 description 1
- 102220006241 rs17602729 Human genes 0.000 description 1
- 102200128173 rs1800091 Human genes 0.000 description 1
- 102200015974 rs1801155 Human genes 0.000 description 1
- 102220150679 rs200318261 Human genes 0.000 description 1
- 102220127052 rs267607568 Human genes 0.000 description 1
- 102200110938 rs28929474 Human genes 0.000 description 1
- 102200143281 rs28931614 Human genes 0.000 description 1
- 102220376509 rs28934601 Human genes 0.000 description 1
- 102200141378 rs28936673 Human genes 0.000 description 1
- 102200059156 rs28940286 Human genes 0.000 description 1
- 102200022128 rs28941783 Human genes 0.000 description 1
- 102200022203 rs28942100 Human genes 0.000 description 1
- 102200128595 rs35516286 Human genes 0.000 description 1
- 102220023971 rs369517993 Human genes 0.000 description 1
- 102220011740 rs386833408 Human genes 0.000 description 1
- 102220005340 rs41412046 Human genes 0.000 description 1
- 102200017290 rs429358 Human genes 0.000 description 1
- 102200092103 rs5742904 Human genes 0.000 description 1
- 102220257091 rs587779976 Human genes 0.000 description 1
- 102200108474 rs587780068 Human genes 0.000 description 1
- 102200114854 rs5985 Human genes 0.000 description 1
- 102200142609 rs6025 Human genes 0.000 description 1
- 102200142355 rs6027 Human genes 0.000 description 1
- 102220046713 rs61754442 Human genes 0.000 description 1
- 102200110918 rs709932 Human genes 0.000 description 1
- 102220056975 rs730880473 Human genes 0.000 description 1
- 102200017284 rs7412 Human genes 0.000 description 1
- 102200132015 rs74503330 Human genes 0.000 description 1
- 102200128182 rs74551128 Human genes 0.000 description 1
- 102200128210 rs74571530 Human genes 0.000 description 1
- 102220075956 rs745767054 Human genes 0.000 description 1
- 102220163582 rs749978636 Human genes 0.000 description 1
- 102220007489 rs75053309 Human genes 0.000 description 1
- 102200128219 rs75527207 Human genes 0.000 description 1
- 102200132008 rs75541969 Human genes 0.000 description 1
- 102200128215 rs75549581 Human genes 0.000 description 1
- 102200143280 rs75790268 Human genes 0.000 description 1
- 102200128617 rs75961395 Human genes 0.000 description 1
- 102200128172 rs76879328 Human genes 0.000 description 1
- 102200128207 rs77646904 Human genes 0.000 description 1
- 102200128590 rs77834169 Human genes 0.000 description 1
- 102200132111 rs77902683 Human genes 0.000 description 1
- 102200128169 rs77932196 Human genes 0.000 description 1
- 102200128171 rs77932196 Human genes 0.000 description 1
- 102220097762 rs779761818 Human genes 0.000 description 1
- 102200132028 rs78194216 Human genes 0.000 description 1
- 102220062133 rs786202780 Human genes 0.000 description 1
- 102200128591 rs78655421 Human genes 0.000 description 1
- 102200132033 rs78769542 Human genes 0.000 description 1
- 102200128179 rs79282516 Human genes 0.000 description 1
- 102200132108 rs80034486 Human genes 0.000 description 1
- 102200128229 rs80055610 Human genes 0.000 description 1
- 102200128599 rs80282562 Human genes 0.000 description 1
- 102220019950 rs80359080 Human genes 0.000 description 1
- 102220213081 rs876660092 Human genes 0.000 description 1
- 102220097351 rs876660522 Human genes 0.000 description 1
- 102220257131 rs920664584 Human genes 0.000 description 1
- 229940110486 salmonella enterica subsp. enterica serovar enteritidis Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000010532 sarcoglycanopathy Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662375396P | 2016-08-15 | 2016-08-15 | |
| US62/375,396 | 2016-08-15 | ||
| PCT/US2017/047029 WO2018035170A1 (en) | 2016-08-15 | 2017-08-15 | Compositions and methods for detecting rare sequence variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3033749A1 true CA3033749A1 (en) | 2018-02-22 |
Family
ID=61197376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3033749A Pending CA3033749A1 (en) | 2016-08-15 | 2017-08-15 | Compositions and methods for detecting rare sequence variants |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10155980B2 (enExample) |
| EP (1) | EP3497245A4 (enExample) |
| JP (3) | JP6966052B2 (enExample) |
| CN (1) | CN109844133A (enExample) |
| CA (1) | CA3033749A1 (enExample) |
| SG (2) | SG10202111825YA (enExample) |
| WO (1) | WO2018035170A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3495506B1 (en) | 2013-12-11 | 2023-07-12 | AccuraGen Holdings Limited | Methods for detecting rare sequence variants |
| US11286519B2 (en) | 2013-12-11 | 2022-03-29 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| US11859246B2 (en) | 2013-12-11 | 2024-01-02 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| HK1259101A1 (zh) | 2015-10-09 | 2019-11-22 | Accuragen Holdings Limited | 用於富集扩增产物的方法及组合物 |
| US12163184B2 (en) | 2015-12-03 | 2024-12-10 | Accuragen Holdings Limited | Methods and compositions for forming ligation products |
| WO2017201102A1 (en) | 2016-05-16 | 2017-11-23 | Accuragen Holdings Limited | Method of improved sequencing by strand identification |
| WO2018035170A1 (en) | 2016-08-15 | 2018-02-22 | Accuragen Holdings Limited | Compositions and methods for detecting rare sequence variants |
| US11203782B2 (en) | 2018-03-29 | 2021-12-21 | Accuragen Holdings Limited | Compositions and methods comprising asymmetric barcoding |
| US20240254547A1 (en) * | 2018-04-27 | 2024-08-01 | Kao Corporation | Highly accurate sequencing method |
| CN112601823A (zh) | 2018-06-12 | 2021-04-02 | 安可济控股有限公司 | 用于形成连接产物的方法和组合物 |
| EP3818166A4 (en) * | 2018-07-05 | 2022-03-30 | AccuraGen Holdings Limited | Compositions and methods for digital polymerase chain reaction |
| KR102321902B1 (ko) * | 2019-01-11 | 2021-11-05 | 주식회사 진캐스트 | Braf 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트 |
| WO2020243108A1 (en) * | 2019-05-28 | 2020-12-03 | Quest Diagnostics Investments Llc | Systems and methods to identify mutations in mitochondrial genomes |
| WO2020263978A1 (en) * | 2019-06-25 | 2020-12-30 | Accuragen Holdings Limited | Methods and systems for disease detection |
| KR20220062302A (ko) * | 2019-08-21 | 2022-05-16 | 라이프 테크놀로지스 코포레이션 | 시퀀싱을 위한 시스템 및 방법 |
| EP3798319A1 (en) | 2019-09-30 | 2021-03-31 | Diagenode S.A. | An improved diagnostic and/or sequencing method and kit |
| EP3828283A1 (en) * | 2019-11-28 | 2021-06-02 | Diagenode S.A. | An improved sequencing method and kit |
| KR102468839B1 (ko) | 2020-06-03 | 2022-11-18 | 주식회사 제노헬릭스 | Rna 검출 방법 |
| WO2022040147A1 (en) * | 2020-08-19 | 2022-02-24 | Accuragen Holdings Limited | Methods for selective cell-free nucleic acid analysis |
| US12371743B2 (en) | 2022-03-04 | 2025-07-29 | Element Biosciences, Inc. | Double-stranded splint adaptors and methods of use |
| US12469162B2 (en) | 2020-08-31 | 2025-11-11 | Element Biosciences, Inc. | Primary analysis in next generation sequencing |
| US12359193B2 (en) | 2022-03-04 | 2025-07-15 | Element Biosciences, Inc. | Single-stranded splint strands and methods of use |
| US20230416824A1 (en) * | 2020-11-17 | 2023-12-28 | World Biotech Regenerative Medical Group Limited | Systems for the detection of targeted gene variations and viral genomes and methods of producing and using same |
| GB202018503D0 (en) * | 2020-11-25 | 2021-01-06 | Olink Proteomics Ab | Analyte detection method employing concatamers |
| EP4047100A1 (en) * | 2021-02-18 | 2022-08-24 | Miltenyi Biotec B.V. & Co. KG | Ngs targeted dna panel using multiplex selective rca |
| WO2022194612A1 (en) * | 2021-03-16 | 2022-09-22 | Miltenyi Biotec B.V. & Co. KG | Method to use dna nanoballs generated by rca using oligonucleotide based dna origami to create high density flowcell for sequencing |
| US20240182951A1 (en) * | 2021-03-31 | 2024-06-06 | Jumpcode Genomics, Inc. | Methods for targeted nucleic acid sequencing |
| JP2024530428A (ja) * | 2021-07-23 | 2024-08-21 | ファウンデーション・メディシン・インコーポレイテッド | バリアント頻度を決定し、疾患進行を監視するための方法 |
| WO2023229999A1 (en) * | 2022-05-24 | 2023-11-30 | Accuragen Holdings Limited | Compositions and methods for detecting rare sequence variants |
| CA3267226A1 (en) | 2022-09-12 | 2024-03-21 | Element Biosciences Inc | DOUBLE STRAND TO STRAND SPLINT ADAPTERS, UNIVERSAL LONG SPLINTS AND METHODS OF USE |
| NL2036501B1 (en) * | 2023-12-12 | 2025-06-20 | Cyclomics B V | Method for sequencing nucleic acid molecules and related methods. |
| WO2025127927A1 (en) * | 2023-12-12 | 2025-06-19 | Cyclomics B.V. | Method for sequencing nucleic acid molecules and related methods |
| WO2025143218A1 (ja) * | 2023-12-28 | 2025-07-03 | デンカ株式会社 | 変異の解析において使用する較正用基準物質としてのゲノムｄｎａを製造する方法、並びに、ゲノムｄｎａ、細胞、及び標的配列の変異を解析する方法 |
| WO2025177174A1 (en) | 2024-02-20 | 2025-08-28 | Diagenode S.A. | Single-cell rna profiling |
Family Cites Families (161)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1015598A (en) | 1908-04-25 | 1912-01-23 | Carborundum Co | Light-refracting material. |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| US5234809A (en) | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
| US6800617B1 (en) | 1989-03-29 | 2004-10-05 | The Johns Hopkins University | Methods for restoring wild-type p53 gene function |
| US6677312B1 (en) | 1989-03-29 | 2004-01-13 | The Johns Hopkins University | Methods for restoring wild-type p53 gene function |
| US5362623A (en) | 1991-06-14 | 1994-11-08 | The John Hopkins University | Sequence specific DNA binding by p53 |
| DE69032864T3 (de) | 1989-03-29 | 2013-01-31 | The Johns Hopkins University | Nachweis des Ausfalls des Wildtyps des p53-Gens |
| US5527676A (en) | 1989-03-29 | 1996-06-18 | The Johns Hopkins University | Detection of loss of the wild-type P53 gene and kits therefor |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| ATE282716T1 (de) | 1989-07-11 | 2004-12-15 | Gen Probe Inc | Verfahren zur amplifikation von nukleinsäuresequenzen |
| US5494810A (en) | 1990-05-03 | 1996-02-27 | Cornell Research Foundation, Inc. | Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease |
| US5527670A (en) | 1990-09-12 | 1996-06-18 | Scientific Generics Limited | Electrochemical denaturation of double-stranded nucleic acid |
| US5352775A (en) | 1991-01-16 | 1994-10-04 | The Johns Hopkins Univ. | APC gene and nucleic acid probes derived therefrom |
| ES2158847T3 (es) | 1991-01-16 | 2001-09-16 | Univ Johns Hopkins | Mutaciones heredadas y somaticas del gen apc en el cancer colorectal del hombre. |
| US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
| US5330892A (en) | 1991-03-13 | 1994-07-19 | The Johns Hopkins University | MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans |
| US5270184A (en) | 1991-11-19 | 1993-12-14 | Becton, Dickinson And Company | Nucleic acid target generation |
| US7326778B1 (en) | 1993-05-05 | 2008-02-05 | The John Hopkins University | Mutator gene and hereditary non-polyposis colorectal cancer |
| US5591826A (en) | 1993-05-05 | 1997-01-07 | The Johns Hopkins University | Human MSH2 protein |
| US5492808A (en) | 1993-05-05 | 1996-02-20 | The Johns Hopkins University | Means for detecting familial colon cancer (FCC) |
| KR960703174A (ko) | 1993-06-09 | 1996-06-19 | 미안 알렉 | 자기장 순환식 반응방법(magnetic cycle reaction) |
| WO1995013375A1 (en) | 1993-11-10 | 1995-05-18 | The Johns Hopkins University | Tumor suppressor waf1 |
| DE69433940T2 (de) | 1993-12-02 | 2005-07-28 | The Johns Hopkins University | Menschliches mutator-gen nmsh2 und seine verbindung zum hereditaren, nichtpolypösen kolorrektalen karzinom |
| US6482606B1 (en) | 1994-01-27 | 2002-11-19 | Human Genome Sciences, Inc. | Human DNA mismatch repair polynucleotides |
| US6380369B1 (en) | 1994-01-27 | 2002-04-30 | Human Genome Sciences, Inc. | Human DNA mismatch repair proteins |
| AU697269B2 (en) | 1994-01-27 | 1998-10-01 | Human Genome Sciences, Inc. | Human DNA mismatch repair proteins |
| US6033850A (en) | 1994-03-15 | 2000-03-07 | Affymetrix, Inc. | Electrochemical denaturation of double-stranded nucleic acid |
| US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
| US5942391A (en) | 1994-06-22 | 1999-08-24 | Mount Sinai School Of Medicine | Nucleic acid amplification method: ramification-extension amplification method (RAM) |
| US6593086B2 (en) | 1996-05-20 | 2003-07-15 | Mount Sinai School Of Medicine Of New York University | Nucleic acid amplification methods |
| US5705628A (en) | 1994-09-20 | 1998-01-06 | Whitehead Institute For Biomedical Research | DNA purification and isolation using magnetic particles |
| US5648245A (en) | 1995-05-09 | 1997-07-15 | Carnegie Institution Of Washington | Method for constructing an oligonucleotide concatamer library by rolling circle replication |
| US5710029A (en) | 1995-06-07 | 1998-01-20 | Gen-Probe Incorporated | Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product |
| US5705365A (en) | 1995-06-07 | 1998-01-06 | Gen-Probe Incorporated | Kits for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| JP3974941B2 (ja) | 1995-11-21 | 2007-09-12 | イェール ユニバーシティ | 単分子セグメントの増幅および検出 |
| US8048629B2 (en) | 1996-03-15 | 2011-11-01 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum |
| US6156504A (en) | 1996-03-15 | 2000-12-05 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays |
| US6511805B1 (en) | 1996-03-15 | 2003-01-28 | The Penn State Research Foundation | Methods for detecting papillomavirus DNA in blood plasma and serum |
| ES2347854T5 (es) | 1996-03-26 | 2014-07-24 | Michael S. Kopreski | Método que permite el uso de RNA extracelular extraído de plasma o suero para detectar, monitorizar o evaluar un cáncer |
| US5939291A (en) | 1996-06-14 | 1999-08-17 | Sarnoff Corporation | Microfluidic method for nucleic acid amplification |
| GB9620209D0 (en) | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
| ATE364718T1 (de) | 1997-04-01 | 2007-07-15 | Solexa Ltd | Verfahren zur vervielfältigung von nukleinsäure |
| GB9706654D0 (en) | 1997-04-02 | 1997-05-21 | Scient Generics Ltd | Disassociation of interacting molecules |
| WO1998045474A1 (en) | 1997-04-04 | 1998-10-15 | Innogenetics N.V. | Isothermal polymerase chain reaction by cycling the concentration of divalent metal ions |
| WO1999053102A1 (en) | 1998-04-16 | 1999-10-21 | Packard Bioscience Company | Analysis of polynucleotide sequence |
| DE69940623D1 (de) | 1998-11-09 | 2009-04-30 | Eiken Chemical | Prozess zur Synthetisierung von Nukleinsäure |
| GB9903906D0 (en) | 1999-02-19 | 1999-04-14 | Microbiological Res Authority | Method and apparatus for nucleic acid strand separation |
| CA2365123A1 (en) * | 1999-03-17 | 2000-09-21 | David R. Cox | Mismatch repair detection |
| JP2002541799A (ja) | 1999-04-12 | 2002-12-10 | ジェネンテック・インコーポレーテッド | Ｐｃｒによるクローニング方法 |
| US20060275782A1 (en) | 1999-04-20 | 2006-12-07 | Illumina, Inc. | Detection of nucleic acid reactions on bead arrays |
| US7056661B2 (en) | 1999-05-19 | 2006-06-06 | Cornell Research Foundation, Inc. | Method for sequencing nucleic acid molecules |
| WO2001018230A1 (en) * | 1999-09-08 | 2001-03-15 | University Of Victoria Innovation & Development Corporation | Use of psychrotrophic bacterium in biotechnology applications |
| IL148091A0 (en) | 1999-09-13 | 2002-09-12 | Nugen Technologies Inc | Methods and compositions for linear isothermal amplification of polynucleotide sequences |
| EP1218543A2 (en) | 1999-09-29 | 2002-07-03 | Solexa Ltd. | Polynucleotide sequencing |
| JP2003515149A (ja) | 1999-11-26 | 2003-04-22 | キュラジェン コーポレイション | 核酸プローブアレイ |
| US6653079B2 (en) | 2000-03-13 | 2003-11-25 | Freshgene, Inc. | Methods for detection of differences in nucleic acids |
| US6917726B2 (en) | 2001-09-27 | 2005-07-12 | Cornell Research Foundation, Inc. | Zero-mode clad waveguides for performing spectroscopy with confined effective observation volumes |
| US6626906B1 (en) | 2000-10-23 | 2003-09-30 | Sdgi Holdings, Inc. | Multi-planar adjustable connector |
| US7001724B1 (en) | 2000-11-28 | 2006-02-21 | Applera Corporation | Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases |
| CA2439477C (en) | 2001-02-27 | 2014-04-15 | Virco Bvba | Circular probe amplification (cpa) using energy-transfer primers |
| WO2002072772A2 (en) | 2001-03-09 | 2002-09-19 | Nugen Technologies, Inc. | Methods and compositions for amplification of rna sequences |
| US7122715B2 (en) | 2001-09-20 | 2006-10-17 | Monsanto Technology Llc | In vitro method to create circular molecules for use in transformation |
| US6977148B2 (en) | 2001-10-15 | 2005-12-20 | Qiagen Gmbh | Multiple displacement amplification |
| US20110151438A9 (en) | 2001-11-19 | 2011-06-23 | Affymetrix, Inc. | Methods of Analysis of Methylation |
| US7553619B2 (en) | 2002-02-08 | 2009-06-30 | Qiagen Gmbh | Detection method using dissociated rolling circle amplification |
| US6815167B2 (en) | 2002-04-25 | 2004-11-09 | Geneohm Sciences | Amplification of DNA to produce single-stranded product of defined sequence and length |
| AU2003272438B2 (en) | 2002-09-20 | 2009-04-02 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
| EP1578994A2 (en) | 2002-11-11 | 2005-09-28 | Affymetrix, Inc. | Methods for identifying dna copy number changes |
| JP2006516410A (ja) | 2003-02-03 | 2006-07-06 | ジーイー・ヘルスケア・バイオサイエンス・コーポレイション | 発現プロファイリングのためのｃＤＮＡ増幅 |
| US20080021205A1 (en) | 2003-12-11 | 2008-01-24 | Helen Blau | Methods and Compositions for Use in Preparing Hairpin Rnas |
| JP2007525571A (ja) | 2004-01-07 | 2007-09-06 | ソレクサ リミテッド | 修飾分子アレイ |
| AU2005216549A1 (en) * | 2004-02-27 | 2005-09-09 | President And Fellows Of Harvard College | Polony fluorescent in situ sequencing beads |
| US20100075384A1 (en) | 2004-03-25 | 2010-03-25 | New England Biolabs, Inc. | Helicase-dependent amplification of circular nucleic acids |
| WO2005113824A2 (en) | 2004-05-14 | 2005-12-01 | Zhenghe Wang | Protein tyrosine phosphatase mutations in cancers |
| US7170050B2 (en) | 2004-09-17 | 2007-01-30 | Pacific Biosciences Of California, Inc. | Apparatus and methods for optical analysis of molecules |
| EP1833994A4 (en) | 2005-01-04 | 2009-09-02 | Hitachi Chemical Co Ltd | ROLLING CIRCLE GAINING OF A PRIMER GENERATION |
| US7588894B2 (en) | 2005-02-01 | 2009-09-15 | John Wayne Cancern Institute | Use of ID4 for diagnosis and treatment of cancer |
| US7824890B2 (en) | 2005-02-19 | 2010-11-02 | Avacta Group Plc | Isothermal amplification of nucleic acids |
| DE602005009324D1 (de) | 2005-04-06 | 2008-10-09 | Maurice Stroun | Methode zur Krebsdiagnose mittels Nachweis von DNA und RNA im Kreislauf |
| US9139849B2 (en) | 2005-04-08 | 2015-09-22 | The United States of America as Represented by the Government of the Department of Health and Human Services | Rapid generation of long synthetic centromeric tandem repeats for mammalian artificial chromosome formation |
| US20060228721A1 (en) | 2005-04-12 | 2006-10-12 | Leamon John H | Methods for determining sequence variants using ultra-deep sequencing |
| EP1907571B1 (en) * | 2005-06-15 | 2017-04-26 | Complete Genomics Inc. | Nucleic acid analysis by random mixtures of non-overlapping fragments |
| WO2007024653A2 (en) | 2005-08-19 | 2007-03-01 | Bioventures, Inc. | Method and substances for isolating micro rnas |
| AU2006320739B2 (en) | 2005-11-28 | 2012-03-29 | Pacific Biosciences Of California, Inc. | Uniform surfaces for hybrid material substrates and methods for making and using same |
| US7537897B2 (en) | 2006-01-23 | 2009-05-26 | Population Genetics Technologies, Ltd. | Molecular counting |
| WO2007092538A2 (en) | 2006-02-07 | 2007-08-16 | President And Fellows Of Harvard College | Methods for making nucleotide probes for sequencing and synthesis |
| WO2007117832A2 (en) | 2006-03-12 | 2007-10-18 | Applera Corporation | Methods of detecting target nucleic acids |
| EP2677039B8 (en) | 2006-05-10 | 2022-10-05 | DxTerity Diagnostics Incorporated | Detection of nucleic acid targets using chemically reactive oligonucleotide probes |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| WO2007140417A2 (en) | 2006-05-31 | 2007-12-06 | Sequenom, Inc. | Methods and compositions for the extraction and amplification of nucleic acid from a sample |
| US7910302B2 (en) | 2006-10-27 | 2011-03-22 | Complete Genomics, Inc. | Efficient arrays of amplified polynucleotides |
| AU2007203390B2 (en) | 2007-04-26 | 2012-10-04 | Yew Jin Fong | Improved lace fastener |
| FR2924440B1 (fr) | 2007-12-04 | 2015-01-09 | Pf Medicament | Nouveau procede de generation et de criblage d'une banque d'anticorps |
| AU2010213510B2 (en) | 2009-02-16 | 2014-05-01 | Epicentre Technologies Corporation | Template-independent ligation of single-stranded DNA |
| WO2010117817A2 (en) | 2009-03-30 | 2010-10-14 | Life Technologies Corporation | Methods for generating target specific probes for solution based capture |
| WO2010115100A1 (en) | 2009-04-03 | 2010-10-07 | L&C Diagment, Inc. | Multiplex nucleic acid detection methods and systems |
| US8962253B2 (en) | 2009-04-13 | 2015-02-24 | Somagenics Inc. | Methods and compositions for detection of small RNAs |
| GB0910302D0 (en) | 2009-06-15 | 2009-07-29 | Lumora Ltd | Nucleic acid amplification |
| US20110237444A1 (en) | 2009-11-20 | 2011-09-29 | Life Technologies Corporation | Methods of mapping genomic methylation patterns |
| US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
| US9315857B2 (en) | 2009-12-15 | 2016-04-19 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse label-tags |
| US8889350B2 (en) | 2010-03-26 | 2014-11-18 | Swift Biosciences, Inc. | Methods and compositions for isolating polynucleotides |
| US9096952B2 (en) | 2010-06-24 | 2015-08-04 | Population Genetics Technologies Ltd. | Methods and compositions for polynucleotide library production, immortalization and region of interest extraction |
| WO2012006291A2 (en) | 2010-07-06 | 2012-01-12 | Life Technologies Corporation | Systems and methods to detect copy number variation |
| US9518295B2 (en) | 2010-08-11 | 2016-12-13 | Institute Of Psychology, Chinese Academy Of Sciences | High-throughput sequencing method for methylated DNA and use thereof |
| EP2426217A1 (en) | 2010-09-03 | 2012-03-07 | Centre National de la Recherche Scientifique (CNRS) | Analytical methods for cell free nucleic acids and applications |
| CN101985654A (zh) | 2010-10-21 | 2011-03-16 | 徐州医学院 | 检测多样本多位点snp的检测方法 |
| US9260753B2 (en) | 2011-03-24 | 2016-02-16 | President And Fellows Of Harvard College | Single cell nucleic acid detection and analysis |
| DK3246416T3 (da) | 2011-04-15 | 2024-09-02 | Univ Johns Hopkins | Sikkert sekventeringssystem |
| WO2014014498A1 (en) | 2012-07-20 | 2014-01-23 | Verinata Health, Inc. | Detecting and classifying copy number variation in a fetal genome |
| WO2013003585A2 (en) | 2011-06-29 | 2013-01-03 | The Johns Hopkins University | Enrichment of nucleic acids by complimentary capture |
| CN103717752B (zh) | 2011-08-05 | 2015-04-15 | 株式会社东芝 | 核酸分析法 |
| WO2013035875A1 (ja) | 2011-09-08 | 2013-03-14 | 独立行政法人理化学研究所 | プライマーセット及びそれを用いた標的核酸配列の増幅方法並びに変異核酸の検出方法 |
| WO2013056178A2 (en) | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| WO2013074632A1 (en) | 2011-11-14 | 2013-05-23 | Rose Floyd D | Mismatch nucleotide purification and identification |
| US20130217023A1 (en) | 2012-02-22 | 2013-08-22 | 454 Life Sciences Corporation | System And Method For Generation And Use Of Compact Clonally Amplified Products |
| EP4234713A3 (en) | 2012-03-20 | 2024-02-14 | University Of Washington Through Its Center For Commercialization | Methods of lowering the error rate of massively parallel dna sequencing using duplex consensus sequencing |
| US8209130B1 (en) | 2012-04-04 | 2012-06-26 | Good Start Genetics, Inc. | Sequence assembly |
| WO2013181170A1 (en) | 2012-05-31 | 2013-12-05 | Board Of Regents, The University Of Texas System | Method for accurate sequencing of dna |
| WO2013181276A1 (en) | 2012-06-01 | 2013-12-05 | Fred Hutchinson Cancer Research Center | Compositions and methods for detecting rare nucleic acid molecule mutations |
| CN104350161A (zh) | 2012-06-14 | 2015-02-11 | 弗莱德哈钦森癌症研究中心 | 用于核酸分子中的敏感突变检测的组合物和方法 |
| US9540687B2 (en) | 2012-07-11 | 2017-01-10 | Berry Genomics Co., Ltd. | DNA fragment detection method, DNA fragment detection kit and the use thereof |
| US9092401B2 (en) | 2012-10-31 | 2015-07-28 | Counsyl, Inc. | System and methods for detecting genetic variation |
| EP2875173B1 (en) | 2012-07-17 | 2017-06-28 | Counsyl, Inc. | System and methods for detecting genetic variation |
| US20140066317A1 (en) | 2012-09-04 | 2014-03-06 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US20160040229A1 (en) | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US20150315636A1 (en) | 2012-10-31 | 2015-11-05 | Becton, Dickinson And Company | Selective amplification and real-time pcr detection of rare mutations |
| EP3939614A1 (en) | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| ES2900102T3 (es) | 2013-02-20 | 2022-03-15 | Univ Emory | Composiciones para la secuenciación de ácidos nucleicos en mezclas |
| US9290800B2 (en) | 2013-03-15 | 2016-03-22 | Pacific Biosciences Of California, Inc. | Targeted rolling circle amplification |
| EP4253558B1 (en) | 2013-03-15 | 2025-07-02 | The Board of Trustees of the Leland Stanford Junior University | Identification and use of circulating nucleic acid tumor markers |
| US10081825B2 (en) | 2013-03-15 | 2018-09-25 | Aegea Biotechnologies, Inc. | Methods for amplification of nucleic acids utilizing a circularized template prepared from a target nucleic acid |
| EP3409791B1 (en) | 2013-03-15 | 2021-06-30 | Verinata Health, Inc. | Generating cell-free dna libraries directly from blood |
| US20150033372A1 (en) | 2013-05-01 | 2015-01-29 | Kymab Limited | Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates |
| US9644232B2 (en) | 2013-07-26 | 2017-05-09 | General Electric Company | Method and device for collection and amplification of circulating nucleic acids |
| US9217167B2 (en) | 2013-07-26 | 2015-12-22 | General Electric Company | Ligase-assisted nucleic acid circularization and amplification |
| WO2015048535A1 (en) | 2013-09-27 | 2015-04-02 | Natera, Inc. | Prenatal diagnostic resting standards |
| EP3058104B1 (en) | 2013-10-17 | 2020-08-19 | Takara Bio USA, Inc. | Methods for adding adapters to nucleic acids and compositions for practicing the same |
| KR20240038168A (ko) | 2013-11-07 | 2024-03-22 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인간 마이크로바이옴 및 그의 성분의 분석을 위한 무세포 핵산 |
| GB201321123D0 (en) | 2013-11-29 | 2014-01-15 | Linea Ab Q | Amplification of circular molecules |
| US11859246B2 (en) | 2013-12-11 | 2024-01-02 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| EP3495506B1 (en) | 2013-12-11 | 2023-07-12 | AccuraGen Holdings Limited | Methods for detecting rare sequence variants |
| US11286519B2 (en) | 2013-12-11 | 2022-03-29 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| EP3378952B1 (en) | 2013-12-28 | 2020-02-05 | Guardant Health, Inc. | Methods and systems for detecting genetic variants |
| CN104745679B (zh) | 2013-12-31 | 2018-06-15 | 杭州贝瑞和康基因诊断技术有限公司 | 一种无创检测egfr基因突变的方法及试剂盒 |
| EP4039811B1 (en) | 2014-01-31 | 2023-09-20 | Integrated DNA Technologies, Inc. | Improved methods for processing dna substrates |
| CA3172086A1 (en) | 2014-06-13 | 2015-12-17 | Illumina Cambridge Limited | Methods and compositions for preparing sequencing libraries |
| CN106661600B (zh) | 2014-07-16 | 2021-04-06 | 唐恩生物科技股份有限公司 | 用于扩增核酸样品的等温方法 |
| US11987836B2 (en) * | 2014-09-30 | 2024-05-21 | Global Life Sciences Solutions Usa Llc | Method for nucleic acid analysis directly from an unpurified biological sample |
| US10844428B2 (en) | 2015-04-28 | 2020-11-24 | Illumina, Inc. | Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS) |
| HK1259101A1 (zh) | 2015-10-09 | 2019-11-22 | Accuragen Holdings Limited | 用於富集扩增产物的方法及组合物 |
| US12163184B2 (en) | 2015-12-03 | 2024-12-10 | Accuragen Holdings Limited | Methods and compositions for forming ligation products |
| WO2017201102A1 (en) | 2016-05-16 | 2017-11-23 | Accuragen Holdings Limited | Method of improved sequencing by strand identification |
| US10370701B2 (en) | 2016-06-17 | 2019-08-06 | Pacific Biosciences Of California, Inc. | Methods and compositions for generating asymmetrically-tagged nucleic acid fragments |
| EP3475449B1 (en) | 2016-06-23 | 2022-08-17 | Accuragen Holdings Limited | Uses of a cell-free nucleic acid standards |
| WO2018035170A1 (en) | 2016-08-15 | 2018-02-22 | Accuragen Holdings Limited | Compositions and methods for detecting rare sequence variants |
| US11203782B2 (en) | 2018-03-29 | 2021-12-21 | Accuragen Holdings Limited | Compositions and methods comprising asymmetric barcoding |
-
2017
- 2017-08-15 WO PCT/US2017/047029 patent/WO2018035170A1/en not_active Ceased
- 2017-08-15 CA CA3033749A patent/CA3033749A1/en active Pending
- 2017-08-15 EP EP17842023.8A patent/EP3497245A4/en active Pending
- 2017-08-15 SG SG10202111825YA patent/SG10202111825YA/en unknown
- 2017-08-15 SG SG11201901296TA patent/SG11201901296TA/en unknown
- 2017-08-15 CN CN201780063576.4A patent/CN109844133A/zh active Pending
- 2017-08-15 JP JP2019508937A patent/JP6966052B2/ja active Active
- 2017-11-01 US US15/800,558 patent/US10155980B2/en active Active
-
2018
- 2018-10-26 US US16/172,310 patent/US10724088B2/en active Active
-
2020
- 2020-06-08 US US16/896,073 patent/US11643683B2/en active Active
-
2021
- 2021-10-11 JP JP2021166929A patent/JP7365382B2/ja active Active
-
2023
- 2023-03-28 US US18/191,792 patent/US20230357836A1/en active Pending
- 2023-10-03 JP JP2023172298A patent/JP2024012298A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180057871A1 (en) | 2018-03-01 |
| JP2024012298A (ja) | 2024-01-30 |
| US20230357836A1 (en) | 2023-11-09 |
| US20190119743A1 (en) | 2019-04-25 |
| JP6966052B2 (ja) | 2021-11-10 |
| WO2018035170A8 (en) | 2018-04-05 |
| EP3497245A4 (en) | 2020-06-03 |
| SG10202111825YA (en) | 2021-12-30 |
| JP2022025083A (ja) | 2022-02-09 |
| JP7365382B2 (ja) | 2023-10-19 |
| US20210355531A1 (en) | 2021-11-18 |
| EP3497245A1 (en) | 2019-06-19 |
| US10155980B2 (en) | 2018-12-18 |
| US10724088B2 (en) | 2020-07-28 |
| WO2018035170A1 (en) | 2018-02-22 |
| JP2019531710A (ja) | 2019-11-07 |
| CN109844133A (zh) | 2019-06-04 |
| SG11201901296TA (en) | 2019-03-28 |
| US11643683B2 (en) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12234512B2 (en) | Compositions and methods for detecting rare sequence variants | |
| US20230357836A1 (en) | Compositions and methods for detecting rare sequence variants | |
| US11859246B2 (en) | Methods and compositions for enrichment of amplification products | |
| US11286519B2 (en) | Methods and compositions for enrichment of amplification products | |
| US20210301328A1 (en) | Compositions and methods for digital polymerase chain reaction | |
| US20250154602A1 (en) | Compositions and methods for detecting rare sequence variants | |
| HK40002630A (en) | Methods for detecting rare sequence variants | |
| HK40002630B (en) | Methods for detecting rare sequence variants | |
| HK1238681A1 (en) | Methods for detecting rare sequence variants | |
| HK1238681B (en) | Methods for detecting rare sequence variants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220720 |
|
| EEER | Examination request |
Effective date: 20220720 |
|
| EEER | Examination request |
Effective date: 20220720 |
|
| EEER | Examination request |
Effective date: 20220720 |